MX2023000045A - Nuevos procesos e intermediarios para la preparacion de estimulantes de guanilato ciclasa soluble. - Google Patents

Nuevos procesos e intermediarios para la preparacion de estimulantes de guanilato ciclasa soluble.

Info

Publication number
MX2023000045A
MX2023000045A MX2023000045A MX2023000045A MX2023000045A MX 2023000045 A MX2023000045 A MX 2023000045A MX 2023000045 A MX2023000045 A MX 2023000045A MX 2023000045 A MX2023000045 A MX 2023000045A MX 2023000045 A MX2023000045 A MX 2023000045A
Authority
MX
Mexico
Prior art keywords
preparation
intermediates
guanylate cyclase
soluble guanylate
compounds
Prior art date
Application number
MX2023000045A
Other languages
English (en)
Inventor
Takashi Nakai
Ahmad Hashash
Song Xue
Vishnu Vardhan Reddy Karnati
Wayne C Schairer
Debra Jane Wallace
Fenger Zhou
Yuguang Wang
William Kissel
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2018/076982 external-priority patent/WO2019161534A1/en
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of MX2023000045A publication Critical patent/MX2023000045A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D263/06Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Procesos nuevos para la preparación de compuestos de Fórmula I. Algunos de estos compuestos son de utilidad como estimulantes de la guanilato ciclasa soluble (sGC). Otros son intermediarios para usar en la preparación de los estimulantes. Estos procesos son adecuados para preparaciones a gran escala y producen 3-(2-pirimidinil)pirazoles de la Fórmula I estables, de gran pureza y rendimientos elevados. La invención ofrece la ventaja adicional de comprender condiciones de reacción sencillas, adecuadas para aumentar la escala en una producción a gran escala. También se proveen nuevos intermediarios para usar en la preparación de los compuestos. (ver Fórmula).
MX2023000045A 2018-01-10 2020-07-13 Nuevos procesos e intermediarios para la preparacion de estimulantes de guanilato ciclasa soluble. MX2023000045A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862615678P 2018-01-10 2018-01-10
PCT/CN2018/076982 WO2019161534A1 (en) 2018-02-22 2018-02-22 Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators

Publications (1)

Publication Number Publication Date
MX2023000045A true MX2023000045A (es) 2023-02-01

Family

ID=65279655

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020007364A MX2020007364A (es) 2018-01-10 2019-01-10 Nuevos procesos e intermediarios para la preparación de estimulantes de guanilato ciclasa soluble.
MX2023000045A MX2023000045A (es) 2018-01-10 2020-07-13 Nuevos procesos e intermediarios para la preparacion de estimulantes de guanilato ciclasa soluble.
MX2023000044A MX2023000044A (es) 2018-01-10 2020-07-13 Nuevos procesos e intermediarios para la preparacion de estimulantes de guanilato ciclasa soluble.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020007364A MX2020007364A (es) 2018-01-10 2019-01-10 Nuevos procesos e intermediarios para la preparación de estimulantes de guanilato ciclasa soluble.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023000044A MX2023000044A (es) 2018-01-10 2020-07-13 Nuevos procesos e intermediarios para la preparacion de estimulantes de guanilato ciclasa soluble.

Country Status (17)

Country Link
US (2) US11274096B2 (es)
EP (2) EP4249469A3 (es)
JP (2) JP7357621B2 (es)
KR (1) KR20200106920A (es)
CN (3) CN118221665A (es)
AU (2) AU2019206560B2 (es)
BR (1) BR112020013985A2 (es)
CA (1) CA3087943A1 (es)
CL (3) CL2020001814A1 (es)
ES (1) ES2963447T3 (es)
IL (1) IL275748A (es)
JO (1) JOP20200165A1 (es)
MA (1) MA51565A (es)
MX (3) MX2020007364A (es)
SG (1) SG11202006311SA (es)
TW (2) TW202402741A (es)
WO (1) WO2019140095A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109563077A (zh) * 2016-07-07 2019-04-02 铁木医药有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的新方法
TW202402741A (zh) 2018-01-10 2024-01-16 美商賽克瑞恩醫療公司 用於製備可溶性鳥苷酸環化酶刺激劑之新穎方法及中間物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2588465T3 (en) * 2010-06-30 2017-05-01 Ironwood Pharmaceuticals Inc SGC stimulators
CN109369635B (zh) * 2013-03-15 2023-06-30 赛克里翁治疗有限公司 化合物或其药学上可接受的盐及其应用和药物组合物
WO2015106268A1 (en) * 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
US20170291889A1 (en) 2014-09-17 2017-10-12 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
CA2961531A1 (en) * 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. Sgc stimulators
KR20180086497A (ko) * 2015-11-30 2018-07-31 아이언우드 파마슈티컬스, 인코포레이티드 sGC 자극제를 포함하는 고체 분산물
JP7054395B2 (ja) 2016-07-07 2022-04-13 サイクレリオン・セラピューティクス,インコーポレーテッド 可溶性グアニル酸シクラーゼ刺激剤の新規な調製方法
CN109563077A (zh) 2016-07-07 2019-04-02 铁木医药有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的新方法
TW202402741A (zh) 2018-01-10 2024-01-16 美商賽克瑞恩醫療公司 用於製備可溶性鳥苷酸環化酶刺激劑之新穎方法及中間物

Also Published As

Publication number Publication date
CN111902410A (zh) 2020-11-06
US20220024909A1 (en) 2022-01-27
CL2022000907A1 (es) 2022-10-21
TW201932450A (zh) 2019-08-16
CL2022000904A1 (es) 2022-10-21
CN111902410B (zh) 2024-04-19
JP2021511299A (ja) 2021-05-06
AU2019206560B2 (en) 2023-08-24
US20210053962A1 (en) 2021-02-25
WO2019140095A8 (en) 2020-06-18
EP4249469A3 (en) 2023-12-27
KR20200106920A (ko) 2020-09-15
TW202402741A (zh) 2024-01-16
BR112020013985A2 (pt) 2020-12-01
MX2023000044A (es) 2023-02-01
CA3087943A1 (en) 2019-07-18
MX2020007364A (es) 2020-11-18
JP7357621B2 (ja) 2023-10-06
CN118221665A (zh) 2024-06-21
ES2963447T3 (es) 2024-03-27
JP2023182647A (ja) 2023-12-26
US11274096B2 (en) 2022-03-15
EP4249469A2 (en) 2023-09-27
US11708361B2 (en) 2023-07-25
US20230339928A1 (en) 2023-10-26
EP3737679C0 (en) 2023-09-06
CL2020001814A1 (es) 2020-11-06
AU2019206560A1 (en) 2020-07-30
MA51565A (fr) 2020-11-18
EP3737679B1 (en) 2023-09-06
IL275748A (en) 2020-08-31
SG11202006311SA (en) 2020-07-29
AU2023270260A1 (en) 2023-12-07
CN118184645A (zh) 2024-06-14
JOP20200165A1 (ar) 2022-10-30
WO2019140095A1 (en) 2019-07-18
EP3737679A1 (en) 2020-11-18
TWI821237B (zh) 2023-11-11

Similar Documents

Publication Publication Date Title
MX2022001495A (es) Procesos novedosos para preparar estimuladores de guanilato ciclasa soluble.
NZ600119A (en) Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
MX2023004157A (es) Composiciones de oligosacaridos para el uso como alimento para animales y sus metodos para producirlas.
JOP20180126A1 (ar) عمليات جديدة من أجل تحضير منشطات محلقة غوانيلات قابلة للذوبان
AU2020317609A8 (en) Novel heteroaryl-triazole compounds as pesticides
MX2023000045A (es) Nuevos procesos e intermediarios para la preparacion de estimulantes de guanilato ciclasa soluble.
MX2018014130A (es) Procedimiento e intermedios para la 6,7-alfa-epoxidacion de 4,6-dienos esteroideos.
PH12019502865A1 (en) Method for preparing intermediate of 4-methoxypyrrole derivative
MX2020006306A (es) Método novedoso para producir 4,5-dihidroisoxazol 5,5-disustituido.
MX2018014128A (es) 6.7.beta-epoxidos esteroideos como intermedios quimicos.
MX2020002449A (es) Nuevos compuestos heterociclicos fungicidas.
PH12019502638A1 (en) Method for preparing intermediate of 4-methoxypyrrole derivative
MX2020012691A (es) Proceso para la sintesis del acido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxilico.
MX362102B (es) Método para producir 4-[5-(piridin-4-il)-1h-1,2,4-triazol-3-il]pir idina-2-carbonitrilo e intermediario del mismo.
AR118647A1 (es) Proceso de preparación de 2-(3,5-diclorofenil)-6-benzoxazolcarboxilato de 1-deoxi-1-metilamino-d-glucitol
MX2021011484A (es) Composiciones de d-metirosina y metodos para preparar las mismas.
MX2021007511A (es) Procedimiento para la preparacion de anilinas sustituidas.
EA202091664A1 (ru) Новые способы и промежуточные соединения для получения стимуляторов растворимой гуанилатциклазы
MX2023000059A (es) Metodo de preparacion de compuesto de fenilisoxazolina.
MX2022002941A (es) Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo.
MX2017009839A (es) Proceso para la produccion de derivados de imidazolo condensados.
MX2017009298A (es) Compuestos de azolobenzazina, composiciones que comprenden estos compuestos, y su uso para controlar plagas de invertebrados.
AR120240A1 (es) Métodos para la preparación de ácido 5-bromo-2-(3-cloro-piridin-2-il)-2h-pirazol-3-carboxílico
MX2022006569A (es) Proceso para la sintesis de una 2-tioalquilpirimidina.
MX2020013768A (es) Carboxilatos de 5(3)-pirazol disustituidos y un proceso para su preparacion a partir de enolatos y reactivos de fluoroalquilamino (far).